EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic Surgery in Alveolar Echinococcosis: Long-Term Outcomes and Practical Recommendations

Lynn Peters, Maria Leuchtner, Wanjie Jiang, Anna-Lena Allgäuer, Alexander Grunenberg, J. Benjamin Hagemann, Andreas Hillenbrand, Marko Kornmann, Beate Grüner

Pathogens · 11.11.2026 · 15 (11) · 1181

DOI: 10.3390/pathogens15111181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 11.11.2026. Verfasst von Lynn Peters und 8 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alveolar echinococcosis (AE) is an infiltrative parasitic liver disease. Surgery remains preferred when feasible, but patient selection and the implications of resection margins remain uncertain.

Methods

We retrospectively analysed 231 surgically treated AE patients first presenting at our centre between 1992 and 2021. A curative outcome required no recurrence on cross-sectional imaging and no ongoing benzimidazole therapy at last follow-up (≥2 years after R0; ≥4 years after R1). Kaplan–Meier analyses assessed recurrence-free survival (R0/R1) and progression-free survival (R2).

Results

R0, R1, and R2 accounted for 42.4%, 19.9%, and 25.1%, respectively. Cure rates were 95.2% (R0) and 88.2% (R1) at ≥4 years post-surgery (p = 0.240). Estimated 10-year recurrence-free survival was 95.1% (R0) and 87.0% (R1; p = 0.183). After R2 resection, 84.0% had stable and 16.0% progressive residual disease. Extensive hepatic involvement (P4) was associated with lower cure rates (p < 0.001).

Conclusions

An R1 margin does not preclude long-term cure and may represent an acceptable surgical endpoint in selected patients with postoperative benzimidazole therapy and imaging surveillance. Planned R2 resections should generally be avoided without specific clinical indications. In advanced disease or when macroscopic residual disease is anticipated, the benefits of surgery should be carefully weighed against medical treatment.

Zitieren

APA

Peters, L., Leuchtner, M., Jiang, W., Allgäuer, A., Grunenberg, A., Hagemann, J. B., Hillenbrand, A., Kornmann, M., & Grüner, B. (2026). Hepatic Surgery in Alveolar Echinococcosis: Long-Term Outcomes and Practical Recommendations. Pathogens, 15(11), 1181. https://doi.org/10.3390/pathogens15111181

Vancouver

Peters L, Leuchtner M, Jiang W, Allgäuer A, Grunenberg A, Hagemann JB, et al. Hepatic Surgery in Alveolar Echinococcosis: Long-Term Outcomes and Practical Recommendations. Pathogens. 2026;15(11):1181. doi:10.3390/pathogens15111181

BibTeX
@article{Peters2026,
  author = {Peters, Lynn and Leuchtner, Maria and Jiang, Wanjie and Allgäuer, Anna-Lena and Grunenberg, Alexander and Hagemann, J. Benjamin and Hillenbrand, Andreas and Kornmann, Marko and Grüner, Beate},
  title = {Hepatic Surgery in Alveolar Echinococcosis: Long-Term Outcomes and Practical Recommendations},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1181},
  doi = {10.3390/pathogens15111181}
}
Kostenlos starten →